Trial Profile

Therapeutic Efficacy Comparison of a Six-month Treatment by Itraconazole and Nebulised Ambisome® Versus Treatment by Itraconazole Alone in Non- or Mildly- Immunocompromised Patients with Chronic Pulmonary Aspergillosis: a Prospective, Randomized, Single Blind Study, (single Aspergilloma Excluded)

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 25 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Amphotericin B liposomal (Primary) ; Itraconazole (Primary) ; Posaconazole; Voriconazole
Indications Aspergillosis; Invasive bronchopulmonary aspergillosis
Focus Therapeutic Use
Acronyms CPAAARI

16 Mar 2023 Planned End Date changed from 1 Jul 2023 to 1 Dec 2029.
16 Mar 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Jun 2027.
09 Feb 2022 Planned primary completion date changed from 1 Jun 2021 to 1 Jun 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com